Office of Commercialization and Economic Development
Office of Technology Commercialization

Prevention of Graft-Versus-Host Disease via A Small Molecule Method of CCR7 Inhibition

Technology #18-0016

UNC data indicates that treatment of stem cells with cosalane prior to transplantation greatly reduces the incidence of aGVHD, while preserving the GVL effect in several transplant models. Our recent studies demonstrated that knock-out of the cc-chemokine receptor 7 (CCR7), by cosalane, in murine T cells impaired their ability to induce aGVHD. Significantly, these T cells retained their graft-versus-leukemia (GVL) response in mouse stem cell transplant models.

Advantages:
-CCR7 inhibition reduces incidence of graft-versus-host disease
-Cosalane-treated T cells retain graft-versus-leukemia responses

Inventors: James Coghill and Kenneth Fowler

Related Publications: